The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
 
Juliet Elizabeth Wolford
No Relationships to Disclose
 
Jiaru Bai
No Relationships to Disclose
 
Ramez Hassef Eskander
No Relationships to Disclose
 
Robin Keller
No Relationships to Disclose
 
Lindsey E Minion
No Relationships to Disclose
 
John K. Chan
Consulting or Advisory Role - AstraZeneca; Biodesix; Clovis Oncology; Janssen Oncology; Mateon Therapeutics; Roche/Genentech
Speakers' Bureau - AstraZeneca; Clovis Oncology; Roche/Genentech
 
Bradley J. Monk
Consulting or Advisory Role - Advaxis; Amgen; AstraZeneca; Bayer; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Insys Therapeutics; Merck; Nucana; Oxigene; Pfizer; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Janssen; Myriad Genetics; Roche/Genentech
Research Funding - Amgen (Inst); Array BioPharma (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Tesaro (Inst)
 
Krishnansu Sujata Tewari
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech